Agouti-related protein (AgRP) and neuropeptide Y (NPY) are colocalized in arcuate nucleus (arcuate) neurons implicated in the regulation of energy balance. Both AgRP and NPY stimulate food intake when administered into the third ventricle and are up-regulated in states of negative energy balance. However, mice with targeted deletion of either NPY or AgRP or both do not have major alterations in energy homeostasis. Using bacterial artificial chromosome (BAC) transgenesis we have targeted expression of a neurotoxic CAG expanded form of ataxin-3 to AgRP-expressing neurons in the arcuate. This resulted in a 47% loss of AgRP neurons by 16 weeks of age, a significantly reduced body weight, (wild-type mice (WT) 34.7±0.7 g vs. transgenic mice (Tg) 28.6±0.6 g, P<0.001), and reduced food intake (WT 5.0±0.2 vs. Tg 3.6±0.1 g per day, P<0.001). Transgenic mice had significantly reduced total body fat, plasma insulin, and increased brown adipose tissue UCP1 expression. Transgenic mice failed to respond to peripherally administered ghrelin but retained sensitivity to PYY 3-36. These data suggest that postembryonic partial loss of AgRP/NPY neurons leads to a lean, hypophagic phenotype.
α-melanocyte stimulating hormone (α-MSH) an agonist of the MC 1, 3, and 4 receptors. Alpha melanocyte stimulating hormone colocalizes with cocaine and amphetamine regulated transcript (CART) in an anorexigenic subset of lateral arcuate neurons. Both AgRP and NPY mRNA are up-regulated in response to fasting and are thought to be important in the regulation of energy homeostasis (5, 6) .
Despite strong pharmacological evidence indicating important roles for AgRP and NPY in the control of energy homeostasis, genetic deletion of either AgRP or NPY does not result in the expected hypophagic, lean phenotype. AgRP knockout mice have normal food intake, body composition, and growth rates. In addition, they have normal responses to fasting, diet-induced obesity, and exogenous leptin and NPY administration (7) . Similarly, NPY knockout mice have normal food intake and body weight, but unlike AgRP-deficient mice, become hyperphagic following food deprivation (8) . In addition, and somewhat surprisingly, NPY knockout mice become obese on a C57 bl/6 genetic background. Mice with targeted deletion of both NPY and AgRP have normal food intake and body weight and maintain a normal response to fasting (7) . Developmental compensation in hypothalamic orexigenic pathways is often cited as a reason for the failure to produce a lean phenotype in these genetic models. Genetic manipulations which occur after critical developmental periods are required to address the problem of developmental compensation. It has also been suggested that the lack of a phenotype in these mice is indicative of a less important role in the regulation of feeding for the arcuate AgRP/NPY neurons than the pro-opiomelanocortin (POMC)/CART neurons.
The function of specific neuroanatomical structures has classically been studied using ablation either chemically or electrically (9) . These methods are relatively nonselective. The advent of genetic manipulation and transgenesis has allowed the development of specific ablation strategies. Placing a gene for a cytotoxin under the regulation of an appropriate expression domain allows ablation of a specific subset of cells. We have used bacterial artificial chromosome (BAC) transgenesis to target the expression of truncated ataxin-3 with a polyglutamine expansion to AgRP/NPY neurons in the arcuate. CAG expanded ataxin-3 causes cell death in several different cell types in vitro (10) . A similar strategy has been used to ablate orexin neurons in vivo with progressive neuronal loss occurring between 4 and 15 weeks (11) .
We report the phenotypic consequences of post-embryonic ablation of AgRP/NPY neurons caused by the specific expression of CAG expanded ataxin-3 in AgRP neurons. These data suggest the AgRP/NPY neuron is a key regulator of energy balance.
MATERIALS AND METHODS

BAC clone modification
A BAC clone (clone 15i23 from CITB-CJ7-B, a kind gift from Dr. G. Barsh, Stanford University) previously used to express Lac Z and cre recombinase in a temporal and spatial pattern that closely resembles AgRP expression was used to target CAG expanded ataxin-3 to AgRP neurons (12) . The BAC clone was modified by inserting CAG expanded ataxin-3 into the start codon of AgRP using a method developed by Zhang et al. (13) (Fig. 1) . PCR was used to amplify cDNAs corresponding to the two homology arms using the BAC as a template. The homology arms corresponded to nucleotides 107088463-107087981, for homology arm 1 (482bp), and nucleotides 107087966-107087447, for homology arm 2 (519bp), on chromosome 8 of the mouse genome, assembly October 2003 from the UCSC genome browser. Truncated ataxin-3 with 77 polyglutamine repeats was amplified using primers corresponding to nucleotides 71-220 of the ataxin-3 gene (accession# BCO33771) using pMJD-Q77 (ΔN286) as a template (kindly donated by Dr T. Yoshizawa, University of Tsukuba). Truncated ataxin-3 was then cloned between homology arm 1 and 2. A floxed spectinomycin resistance gene (Sp) was isolated from pDLOX5 (a kind gift from Dr. C. Huxley, Imperial College London) and inserted between ataxin-3 and homology arm 2 ( Figure 1 ). Homologous recombination between the linear modification cassette and the BAC clone was carried out as described previously (14) . Recombinant BACs were identified by spectinomycin resistance and correct integration verified by PCR. To verify correct 5′ integration: the forward primer used was outside the region of homology arm 1 and the reverse primer for the ataxin-3 gene was used. 3′ integration was verified using a forward primer in the Sp gene and a reverse primer to the 3′ end outside the region of homology arm 2. Further verification by restriction digest and southern blotting was performed. The floxed Sp resistance gene was removed from the modified clones using plasmid pJM2545 (a kind gift from Dr. C. Huxley) as described previously (15) . Successful removal was confirmed by positive negative selection and PCR using primers described above and southern blotting.
Transgenic mouse lines
BAC transgene constructs were purified using the Qiagen Large Construct Kit (Qiagen, Valencia, CA). Circular modified BAC molecules were injected into pronuclei of CBA/C57Bl6 F1 fertilized eggs following standard microinjection procedures by the MRC Clinical Research Centre Transgenic Research Facility, Hammersmith Hospital London. Transgenic (Tg) founder (F0) mice were identified by PCR using primers derived from the pBeloBAC sequence, 5′-TCATTCTGCAATCGGCTTGC-3′ (forward) and 5′-GTGCCTGGAGAAATGCTC TT -3′ (reverse). To establish transgenic lines, F0 mice were mated with CBA/C57Bl6 mice, and transgenic lines were maintained by mating transgenic offspring of a single founder. Mice were maintained in cages under controlled temperature (21-23°C) and light (11-h light/13-h dark) with ad libitum access to food (RM3 diet, SDS UK Ltd.) and water. Animal procedures performed were approved under the British Home Office Animals Scientific Procedures Act 1986 (Project license numbers 70/5138 and 70/5516). All experiments shown were conducted using male mice, however, a broadly similar phenotype was observed in transgenic females.
In situ hybridization
In situ hybridization (ISH) was performed, as described previously (16) . A radiolabeled ataxin-3 probe corresponding to nucleotides 71-220 of the ataxin-3 gene (accession# BCO33771), a radioactively or digoxigenin-labeled AgRP probe corresponding to nucleotides 110-520 of the AgRP mouse gene (accession# U89486), or a digoxigenin labeled POMC probe corresponding to nucleotides 64-467 of exon 3 of the mouse POMC gene (accession# AH005319) were used. Riboprobes were labeled with either 35 S CTP (Amersham Biosciences, Little Chalfont, Bucks, UK) or digoxigenin-CTP (DIG RNA Labeling mix, Roche Diagnostics, Mannheim, Germany). Hybridization buffer was supplemented with probe at a rate of 1 × 10 5 Bq/μl for radio-labeled probes and 2.5 ng/μl for digoxigenin-labeled probes and incubated overnight at 60°C. Subsequently, slides were RNase-A treated, washed, air-dried, and exposed to autoradiographic film (Bio-Max Film MR, Kodak, Hemel Hempstead, Herts, UK). For digoxigenin-labeled probes: following the final wash step after hybridization, slides were blocked for two hours in 0.1 M Tris, 0.15 M NaCl, 5% FBS, 0.05% Tween pH 7.5. Sections were then incubated for a further 2 h at room temperature with 350 μl of anti-digoxigenin-alkaline phosphatase Fab fragments (Roche Diagnostics) diluted 1:2000 in the blocking buffer. Sections were rinsed twice for 5 min in 0.1 M Tris, 0.15 M NaCl, 0.05% Tween pH 7.5 and for 5 min in the same buffer at pH 9.5. The alkaline phosphatase was developed using a BCIP/NBT kit (Vector Laboratories, Burlingame, CA) following the manufacturer's instructions. A representative AgRP or POMC cell number for each animal was calculated by counting bilateral AgRP and POMC cell numbers in 16 sections matched throughout the rostro-caudal extent of the arcuate by a researcher blinded to the genotype of the mice.
Static incubation of hypothalamic explants
The static incubation system used was as described previously (17) . Briefly, weight-matched male mice were killed by cervical dislocation and the whole brain immediately removed. The brain was mounted with ventral surface uppermost and placed in a vibrating microtome (Microfield Scientific Ltd., Dartmouth, UK). A 1.7 mm slice was taken from the basal hypothalamus and blocked lateral to the Circle of Willis. The hypothalamic slices were incubated in artificial cerebrospinal fluid (aCSF) at 37°C for an initial 2 h equilibration period. The hypothalami were incubated for 45 min in aCSF containing 56 mM KCl; isotonicity was maintained by substituting K + for Na + . The aCSF was collected and stored at -20°C until measurement of AgRP-immunoreactivity (IR), NPY-IR, α-MSH-IR, and CART-IR by radioimmunoassay.
Radioimmunoassays
Radioimmunoassays for NPY-IR, α-MSH-IR, and CART-IR were performed using established methods (18, 19) . AgRP-IR was measured using reagents and methods from Phoenix Pharmaceuticals Inc. Belmont, CA, following the manufacturer's protocol.
The CART antiserum was produced in-house and has been described previously (20, 21) . The CART antiserum was used at a final dilution of 1:28000. Commercially available CART fragments were tested for cross-reactivity. The assay showed 20% cross-reaction with CART-(61-102) and CART-(62-102) and <0.1% cross-reaction with CART-(1-39) (Phoenix Pharmaceuticals, Belmont, CA). The assay also showed <0.1% cross-reaction with 1 nmol/tube of AgRP, arginine vasopressin, bombesin, brain natriuretic peptide, calcitonin gene-related peptide, follicle-stimulating hormone, galanin, glucagons, growth hormone-releasing hormone, NPY, oxytocin, prolactin, prolactin-releasing peptide, somatostatin, and substance P. The CART assay had a sensitivity of 1.25 ± 0.5 (SE) fmol/tube, n = 4, with 95% confidence. The midrange was 16.2 ± 0.9 fmol/tube, n = 8. The specific activity of freshly prepared CART-(55-102) peptide label, as estimated by self-displacement in the assay, was 42 Bq/fmol. The intra-and interassay variation was 8% and 9%.
The NPY antiserum was produced in-house and has been previously characterized (22) . The final dilution of antibody was 1:24000 and showed no cross-reactivity with porcine pancreatic polypeptide or porcine peptide YY in concentrations up to 100 pmol/tube. The specific activity of iodinated NPY as measured by self displacement was 40 Bq/fmol. The intra-and interassay variation was 7% and 8%.
The α-MSH antibody was obtained from Chemicon International, CA, catalog number AB5087. This antibody has been previously characterized by Elias et al. (23) . Briefly, the antiserum is specific for α-MSH with no cross reactivity with MCH and is dependent on the amidated Cterminal region for recognition. Cross reactivities of the antiserum with related peptides are desacetyl-α-MSH, 82-100%; α-MSH-free acid, 0.018%; β-MSH (monkey), < 0.0018%; α-MSH (11-13), γ1-MSH, and γ2-MSH (each undetectable at 1 µM); ACTH (1-10), 0.018%; ACTH (1-24), 0.02%; ACTH (1-39) (human), 0.022%; β-LPH (human), 0.022%; β-endorphin (human), and γ-endorphin (each undetectable at 1 µM). The sensitivity of the assay was 1fmol/ml. The specific activity of iodinated α-MSH as measured by the self displacement assay was 55 Bq/fmol. The intra-and interassay variation was 7% and 8%.
Phenotypic characterization
Male mice were singly housed from weaning and their food intake and body weight measured between 0900 and 1000 three times a week. At sixteen weeks of age mice were killed in the early light phase by inhalation of carbon dioxide, whole blood collected for hormone-level analysis, epididymal fat pads removed and weighed and brown adipose tissue (BAT) removed and snap frozen.
Body composition
Body composition was calculated using the method of Salmon and Flatt (24) . Glycerol was measured using a colorimetric assay (Randox, Crumlin, Co Antrim, UK).
Measurement of circulating hormones and glucose
Whole blood was collected using heparinized syringes and cardiac puncture from fasted 16-week-old mice killed by CO 2 inhalation. Blood was mixed with 20 μl of aprotinin (Trasylol, Bayer, Haywards Heath, UK) plasma was separated and stored at -20°C until measurement of plasma hormones by ELISA or measurement of glucose using YSI 2300 STAT plus (Analytical Technologies). Mouse plasma insulin and leptin concentrations were determined using reagents and methods from Crystal Chem Inc. (Downers Grove, IL).
Northern blot analysis
A cDNA corresponding to nucleotides 368-687 of the mouse uncoupling protein-1 (UCP1) (accession# BC012701) was generated from total BAT RNA by RT-PCR with the specific primers 5′-AAGGCCAGGCTTCCAGTACTATTAGG-'3 (forward) and '5-GGTTTGATCCCATGCAGATGGCTCTG-'3 (reverse). Northern blot analysis was performed as described previously (25) . The filters were exposed to storage phosphor screens (Molecular Dynamics, Amersham Sciences) and quantified using a Storm imaging system (Molecular Dynamics, Amersham Sciences). The ratio of specific message to 28S rRNA was used to quantify expression for each tissue sample.
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Peripheral administration of ghrelin and PYY 3-36
At 10 wk of age, ad libitum fed mice were given ghrelin by intraperitoneal (ip) injection, and their food intake was measured. Studies were a randomized, blinded crossover design with half the mice receiving 0.01 M PBS on study day 1 followed by 0.3 nmol/g ghrelin (26) on study day two; the remaining mice received ghrelin on day 1 and PBS on day 2. A recovery period of two days was allowed between each study day. Mice were injected ip in the early light phase at 0900 h. Food intake was measured at 2 h postinjection.
At 11 weeks of age, mice were given PYY3-36 by ip injection. For the ghrelin studies, mice were investigated using a randomized, blinded crossover design. Before each study day, mice were fasted for 24 hours and PYY3-36 at a dose of 10 μg/100 g (27) was administered at 0900. After PYY3-36 administration, food intake was measured at 2 h postinjection.
Statistical analysis
Values are the means ± SEM unless otherwise stated. For analysis of the effect of peripheral administration of ghrelin and PYY3-36, a paired Student's t test with a Bonferroni's correction was used. All other comparisons were made using an unpaired Student's t test. P values < 0.05 were considered significant.
RESULTS
Transgene expression
Brains from 3-wk-old mice were examined by dual in situ hybridization using a digoxigenin labeled AgRP riboprobe and a radio-labeled ataxin-3 riboprobe to investigate transgene expression. Strong ataxin-3 expression was present in the midbrain in both WT and Tg mice (data not shown). This expression correlated with published data, which has shown that endogenous ataxin-3 is expressed in the cerebellum, striatum, and thalamus (28) . Ataxin-3 expression was also evident in the arcuate of Tg mice but not WT mice. Ataxin-3 expression in the arcuate of Tg mice was colocalized in AgRP expressing neurons ( Fig. 2A, B) . This suggested BAC-driven expression of the neurotoxic CAG-expanded ataxin-3 transgene was successfully directed to AgRP expressing neurons. However, the ataxin-3 transgene did not appear to be expressed in every AgRP-containing neuron, indicating that transgene expression was either below the limit of detection in these cells or that transgene expression had been silenced in these neurons.
AgRP cell loss
At 3 wk of age, we found a significant 20% loss of AgRP-containing neurons in Tg mice compared with controls (473±20 cells WT vs. 379±29 cells Tg n=4, P<0.05, Fig. 2C-E) . By 16 wk of age, a further (47%) loss of AgRP-containing neurons was observed in the arcuate of Tg mice compared with controls (699±66 cells WT vs. 368±78 cells Tg, n=5, P<0.05, Fig. 3A, B) . In addition, ataxin-3 expression was undetectable in the arcuate of either 7-or 16-wk-old Tg mice (data not shown). These observations suggested that the transgene was not expressed or silenced in half of the AgRP neurons, while the remaining transgene-positive AgRP neurons exhibited a
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progressive postnatal degeneration until 7 wk of age. To investigate the possibility of a bystander effect, POMC cell numbers in the arcuate were investigated. POMC neuronal numbers were identical in WT and Tg mice (663±43 cells WT vs. 602±26 cells Tg, n=4, P=0.27, Fig. 3C-E) , suggesting cell loss was likely to be specific for AgRP neurons and no bystander effect was evident.
Hypothalamic explants
To investigate the function of the remaining AgRP/NPY neurons and the consequences of AgRP/NPY neuronal cell loss on α−MSH/CART neuronal function, release of AgRP-IR, NPY-IR, α-MSH-IR, and CART-IR from ex vivo hypothalamic slices from weight-matched mice was measured. Release of AgRP-IR was significantly reduced by 20% in hypothalamic explants from Tg mice (WT 1.72±0.13 fmol/explant (n=7) vs. Tg 1.37±0.08 fmol/explant (n=12), P<0.05, Fig.  4A ). There was also a 33% reduction in NPY-IR release in Tg mice (WT 32.3±3.7 fmol/explant (n=8) vs. Tg 22.3±3.1 fmol/explant (n=12), P=0.054, Fig. 4B ). Release of both α-MSH-IR (WT 10.67±1.04 fmol/explant (n=7) vs. Tg 10.78±1.14 fmol/explant (n=12), P=0.9, Fig. 4C ) and CART-IR (WT 428±53.5 fmol/explant (n=8) vs. Tg 392±66.7 fmol/explant (n=12), P=0.7, Fig.  4D ) was the same in WT and Tg mice.
Phenotypic characterization
Transgenic mice were significantly lighter than their age-matched WT controls at weaning (3 wk), WT 10.5 ± 0.5 g (n=9) vs. Tg 7.4 ± 0.4 g (n=14) P < 0.001 (Fig. 5A ). From 7 wk of age, Tg mice gain weight at a slower rate than their controls. This trend of slower growth in Tg mice increased with age: at 16 wk of age, wild-type mice were 34.7 ± 0.7 g, while Tg mice were 28.6 ± 0.6 g (P<0.001) (Fig. 5A ).
Food intake was significantly reduced in Tg mice (Fig. 5B) . Tg mice between the ages of 4 and 6 wk ate on average 16% less per day than controls (WT 4.2±0.05 g (n=9) vs. Tg 3.5±0.1 g (n=14), P<0.0005). The difference in food intake was further increased by 14-16 wk of age when the difference in average daily food intake was 28% (5.0±0.24 g WT vs. 3.6±0.12 g Tg, P<0.0005). Over the course of the study, daily food intake in the Tg mice appeared to remain relatively constant 3.5 ± 0.1 g/day at 4 to 6 weeks and 3.6 ± 0.12 g/day at 14-16 weeks (P=0.6). However, daily food intake in WT mice steadily increased with age and weight rising from an average of 4.17 ± 0.05 g/day at 4 to 6 weeks to 5.01 ± 0.24 g/day by 14 to 16 weeks of age (P<0.01).
To investigate whether the difference in food intake observed between age-matched control and Tg mice might be the result of differences in body weight between the two groups, average daily food intake was analyzed over a 2-week period in mice aged 14-16 wk of age and adjusted for body weight. When food intake was adjusted for body weight, average daily food intake in Tg mice was significantly reduced by 16% compared with controls (WT 0.149±0.01 g/g of body weight vs. Tg 0.126±0.005 g/g of body weight, P<0.01, Fig. 5C ). Similar effects were seen in females and two other independent transgenic lines.
Body composition
At 16 wk of age, Tg mice had a significant 15% reduction in epididymal white adipose tissue (WAT) weight compared with WT mice (WT 0.88±0.07 g vs. Tg 0.66±0.08 g, P<0.05, (Fig. 6A) . Total body fat was reduced by 53% in Tg mice compared with WT mice (WT 11.2±1.6 g (n=3) vs. Tg 5. 28±0.36 g (n=4), P<0.05, Fig. 6B ). However, lean mass was identical between Tg and WT mice (WT 20.9±0.99 g (n=3) vs. Tg 20. 2±2.18 g (n=4), P=0.77, Fig. 6C ).
Leptin, insulin, and glucose levels
Circulating leptin was 27% lower in the transgenic mice (WT 4.1±0.6ng/ml vs. Tg 3.1±0.6 ng/ml, n=4, P=0.075, Fig. 6D ). There was a significant reduction of 53% in circulating insulin levels in Tg mice compared with WT (WT 1.02±0.13 ng/ml vs. Tg 0.48±0.14 ng/ml, n=4, P<0.05, Fig. 6E ). There was no difference in circulating glucose between the two groups (WT 12.9±1.4mmol/l (n=11) vs. Tg 11.2±1.1mmol/l (n=9), P=0.39, Fig. 6F ).
UCP1 mRNA levels
UCP1 mRNA expression in BAT was increased in Tg mice to 146% compared with WT mice (n=7), P<0.05, Fig. 6G ).
Peripheral administration of ghrelin and PYY 3-36
Ghrelin significantly increased food intake 2 h postinjection in ad libitum-fed WT mice (0-2 h food intake in saline-treated WT mice 0.06±0.03 g vs. ghrelin-treated WT mice 0.39±0.06 g n=4, P<0.01). Ghrelin failed to stimulate food intake in ad libitum-fed Tg mice (saline-treated Tg mice 0.08±0.02 g vs. ghrelin-treated Tg mice 0.10±0.02 g, P=0.46, Fig. 7A ).
PYY 3-36 significantly reduced food intake 2 h postinjection in WT and Tg mice fasted for 24 hours. Food intake in saline-treated WT mice was 2.03 ± 0.15 g and when treated with PYY 3-36 was 1.55 ± 0.13 g (P<0.05), a 24% reduction in food intake. The reduction in food intake was similar to that reported in the literature (27, (29) (30) (31) . Food intake in Tg mice was 1.49 ± 0.18 g when treated with saline and 1.09 ± 0.17 g when given PYY 3-36 (P<0.05), a 27% reduction in food intake (Fig. 7B) .
DISCUSSION
A BAC clone was used to target expression of a neurotoxic CAG-expanded ataxin-3 transgene in arcuate AgRP/NPY neurons. Expression of the transgene in AgRP/NPY neurons resulted in the loss of 47% of these neurons by 16 wk of age, while POMC neuron numbers were unaffected. This suggests ablation was specific for AgRP/NPY neurons and that expression of the transgene occurred in only half of the AgRP/NPY neurons or that expression in half the neurons was insufficient to kill them and below the limit of detection of the ISH.
Functionally, the loss of 47% of AgRP/NPY neurons in Tg mice resulted in a reduction in the release of AgRP-IR and NPY-IR from hypothalamic explants, by 20% and 30%, respectively. Because almost 50% of AgRP/NPY neurons had been lost, the reduction in AgRP-IR and NPY-
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IR might be expected to match this. The more modest decrease could be the result of upregulation of the activity of the remaining AgRP/NPY neurons in response to the decreased adiposity in Tg mice.
Transgenic mice had reduced food intake and increased BAT UCP-1 mRNA levels. The increased UCP-1 mRNA levels would be expected to result in increased energy expenditure. In combination, these alterations would result in reduced body weight as seen in Tg mice. AgRP and NPY are both powerful orexigenic agents (32, 33) . Therefore this hypophagic phenotype might be expected following a loss of arcuate AgRP/NPY neurons. These neurons also directly inhibit sympathetic outflow to BAT decreasing energy expenditure (34, 35) . Therefore, loss of AgRP/NPY neurons would be expected to increase UCP1 mRNA as seen in our Tg mice.
The changes in food intake and body weight observed in the Tg mice are in contrast to the normal energy regulation in mice with targeted deletion of AgRP, NPY, or both and could be due to several reasons. First, recent data suggest the period immediately following birth, postnatal day 4 to day 12, is a critical time during which the hypothalamus is highly plastic, particularly to the trophic actions of leptin (36) . This plasticity is lost at later stages of development. Our data suggest that at least half the ablated AgRP neurons are lost postweaning at 3 wk of age. Therefore, loss of at least half of the ablated AgRP neurons in our Tg mice occurs after the critical period during which compensatory changes in neuronal connections take place. The presence of compensatory mechanisms in the embryo is supported by a recent report demonstrating that a 50% reduction of AgRP expression by RNA interference in adult mice resulted in an increased metabolic rate and reduced body weight (37) . Second, loss of AgRP/NPY neurons may also precipitate the loss of another unknown colocalized orexigenic factor which would still be present in mice with targeted deletion of AgRP, NPY, or both.
Transgenic mice displayed a 53% (5.88 g) reduction in total body fat at 16 weeks of age. The reduced adiposity in Tg mice is consistent with the reduction in food intake and an increase in energy expenditure indicated by the increase in UCP1. This reduced body fat accounts for the difference in body weight between WT and Tg mice, since Tg mice are 6.0 g lighter than WT mice but have identical lean mass at 16 weeks of age. The reduction in adiposity in Tg mice was associated with the expected lowering of circulating plasma leptin levels and improved insulin sensitivity as shown by their reduced plasma insulin levels in the presence of normal circulating glucose levels.
Hormones released from the stomach signal to the brain via arcuate AgRP/NPY neurons. Ghrelin is a circulating peptide released from the stomach (38, 39) , which stimulates food intake when given peripherally to mice, rats, and humans (39, 40) . Ghrelin is thought to act via AgRP/NPY containing neurons in the arcuate (41) (42) (43) . PYY3-36 is a gut hormone, which is also released into the circulation and is thought to be a potent satiety factor in mice, rats, and man (38) . PYY is an agonist of the Y 2 autoreceptor and is thought to act in the arcuate where it has been shown to decrease NPY mRNA and increase POMC mRNA expression (27, 44) .
Transgenic mice that have a 47% reduction in AgRP/NPY neurons failed to respond to peripherally administered ghrelin. The same effect was found in mice with targeted deletion of both AgRP and NPY but not those with deletion of either alone (45) . However, Tg mice retain their sensitivity to PYY3-36. A possible explanation for these results is that the remaining AgRP/NPY neurons in Tg mice may be maximally active in an attempt to compensate for their reduced number. This would be in keeping with the more modest than expected fall in AgRP and NPY release from Tg hypothalamic explants and the failure of Tg mice to increase food intake with age during the study period. In this situation, ghrelin, which stimulates these neurons, will be unable to increase their activity further, therefore failing to increase food intake. In contrast, PYY3-36, which acts by inhibiting AgRP/NPY neuronal function, would still be able to inhibit activity of these neurons, resulting in decreased food intake.
In summary, a reduction in the number of arcuate AgRP/NPY neurons after embryogenesis in mice leads to a lean, hypophagic phenotype and suggests that the AgRP/NPY neuron has a critical role in the regulation of appetite and body weight. WT (solid circle) controls. B) Tg mice (light gray bars) have a significantly lower average daily food intake compared with WT mice (dark gray bars) at 14-16 wk of age. *P < 0.0005. C) Average daily food intake adjusted for body weight is significantly lower in Tg mice (light gray bars) compared with WT controls (dark gray bars) at 14-16 wk of age. *P < 0.01. 6 . Epididymal WAT weight, total body fat, lean body mass, circulating leptin, insulin, glucose, and BAT UCP1 levels. A) There was a significant 15% reduction in epididymal WAT weight in Tg mice. B, C) There was a significant 53% reduction in total body fat in Tg mice, while there was no difference in lean mass, D) Leptin levels were reduced by 27%. E) Insulin levels were reduced by 53% in Tg mice, whereas glucose levels remained unaltered between WT and Tg mice (F). G) BAT UCP1 mRNA levels were significantly increased to 146% in Tg mice compared with WT. *P < 0.05. libitum fed WT mice but did not increase food intake in ad libitum fed Tg mice. *P < 0.01, n=4. B) PYY 3-36 (10 µg/100 g ip) reduced food intake in the first 2 h postinjection in both 24-h fasted WT and Tg mice. *P = < 0.05, n = 4. S = saline, G = ghrelin, P = PYY 3-36.
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